HRMY
Harmony Biosciences Holdings, Inc.NASDAQHealthcare$27.74-0.79%ClosedMarket Cap: $1.60B
As of 2026-04-06
Valuation
P/E (TTM)
10.11
PEG
1.11
P/B
1.84
P/S
1.85
EV/EBITDA
4.33
DCF Value
$127.52
FCF Yield
21.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.2%
Operating Margin
24.0%
Net Margin
18.3%
ROE
19.8%
ROA
12.5%
ROIC
13.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $243.8M | 71.9% | $38.6M | $22.5M | $0.38 | — |
| FY 2025 | $868.5M | 77.2% | $208.5M | $158.7M | $2.71 | — |
| Q3 2025 | $239.5M | 75.1% | $65.5M | $50.9M | $0.87 | — |
| Q2 2025 | $200.5M | 81.0% | $48.2M | $39.8M | $0.68 | — |
| Q1 2025 | $184.7M | 82.7% | $56.2M | $45.6M | $0.78 | — |
| Q4 2024 | $201.3M | 73.0% | $55.7M | $49.5M | $0.85 | — |
| FY 2024 | $714.7M | 78.1% | $190.8M | $145.5M | $2.51 | — |
| Q3 2024 | $186.0M | 77.0% | $61.7M | $46.1M | $0.79 | — |
| Q2 2024 | $172.8M | 81.4% | $21.4M | $11.6M | $0.20 | — |
| Q1 2024 | $154.6M | 82.2% | $52.0M | $38.3M | $0.67 | — |
| Q4 2023 | $168.4M | 74.4% | $40.2M | $26.6M | $0.45 | — |
| FY 2023 | $582.0M | 79.2% | $192.0M | $128.9M | $2.13 | — |